Hosseini Sayed Mostafa, Soltani Bahram Mohammad, Tavallaei Mahmoud, Mowla Seyed Javad, Tafsiri Elham, Bagheri Abouzar, Khorshid Hamid Reza Khorram
Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Human Genetic Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Avicenna J Med Biotechnol. 2018 Apr-Jun;10(2):98-104.
The cyclin E2 (CYCE2) is an important regulator in the progression and development of NSCLC, and its ectopic expression promoted the proliferation, invasion, and migration in several tumors, including Non-Small Cell Lung Cancer (NSCLC). However, the upregulation of CYCE2 in NSCLC cells suggested that it has a key role in tumorigenicity. In addition, the RAS family proteins as oncoproteins were activated in many major tumor types and its suitability as the therapeutic target in NSCLC was proposed. Considering the crucial role of microRNAs, it was hypothesized that altered expression of and might provide a reliable diagnostic tumor marker for diagnosis of NSCLC.
Real-time RT-PCR approach could evaluate the expression alteration of and and it was related to the surgically resected tissue of 24 lung cancer patients and 10 non-cancerous patients. The miRNAs expression was associated with clinicopathological features of the patients.
showed a significant downregulation (p=0.0382) in resected tissue of NSCLC patients compared with control group. Its expression level could differentiate different stages of malignancies from each other. The ROC curve analysis gave it an AUC=0.73 (p=0.037) which was a good score as a reliable biomarker. In contrast, was significantly overexpressed in tumor samples (p=0.03). Interestingly, our findings revealed a significant association of in adenocarcinoma tumors, compared to Squamous Cell Carcinomas (SCC) (p<0.05). Also, analysis of ROC curve of (AUC=0.74, p-value=0.042) suggests that it could be as a suitable biomarker for NSCLC.
Together, these results suggest a possible tumor suppressor role for in lung tumor progression and initiation. Moreover, upregulation of was associated with the tumor type.
细胞周期蛋白E2（CYCE2）是NSCLC进展和发展中的重要调节因子，其异位表达促进了包括非小细胞肺癌（NSCLC）在内的多种肿瘤的增殖、侵袭和迁移。然而，CYCE2在NSCLC细胞中的上调表明它在肿瘤发生中起关键作用。此外，RAS家族蛋白作为癌蛋白在许多主要肿瘤类型中被激活，并有人提出其作为NSCLC治疗靶点的适用性。考虑到微小RNA的关键作用，推测 和 的表达改变可能为NSCLC的诊断提供可靠的肿瘤标志物。
实时逆转录聚合酶链反应（RT-PCR）方法可评估 和 的表达变化，其与24例肺癌患者和10例非癌患者的手术切除组织相关。微小RNA的表达与患者的临床病理特征相关。
与对照组相比，NSCLC患者切除组织中 显著下调（p=0.0382）。其表达水平可区分恶性肿瘤的不同阶段。ROC曲线分析得出其曲线下面积（AUC）=0.73（p=0.037），作为可靠的生物标志物得分良好。相比之下， 在肿瘤样本中显著过表达（p=0.03）。有趣的是，我们的研究结果显示，与鳞状细胞癌（SCC）相比， 在腺癌肿瘤中有显著相关性（p<0.05）。此外， 的ROC曲线分析（AUC=0.74，p值=0.042）表明它可能是NSCLC的合适生物标志物。
总之，这些结果表明 在肺肿瘤进展和起始中可能具有肿瘤抑制作用。此外， 的上调与肿瘤类型相关。
